Literature DB >> 17356336

Neuropsychologic assessment of patients with advanced Parkinson disease submitted to extradural motor cortex stimulation.

Donato Munno1, Silvia Caporale, Giuseppina Zullo, Sara Sterpone, Alessandro Malfatto, Sergio Zeme, Carlo A Pagni.   

Abstract

OBJECTIVE: The aim of this study was to evaluate changes in cognitive functioning and emotive state in 3 inpatients with advanced Parkinson disease (PD) treated with extradural motor cortex stimulation (EMCS), an experimental neurosurgical procedure.
BACKGROUND: Studies on the neuropsychologic assessment of patients with PD after EMCS are in process. The procedure has been applied for some years as an experimental method for treating PD.
METHOD: A battery of neuropsychologic tests and emotive assessment scales were administered to 3 inpatients with PD 2 days before the intervention and then again after 1 year to evaluate changes in cognitive functioning and emotive state.
RESULTS: At 1-year postintervention, cognitive functions and depressive symptoms were steady; 2 patients showed a mild improvement in quality of life.
CONCLUSIONS: In this patient group, EMCS, an experimental neurosurgical treatment, had a positive effect on motor symptoms. Neuropsychologic assessment after a 1-year follow-up period showed that cognitive functions had not changed with respect to baseline characteristics.

Entities:  

Mesh:

Year:  2007        PMID: 17356336     DOI: 10.1097/WNN.0b013e31802b6c0b

Source DB:  PubMed          Journal:  Cogn Behav Neurol        ISSN: 1543-3633            Impact factor:   1.600


  2 in total

1.  Extradural Motor Cortex Stimulation might improve episodic and working memory in patients with Parkinson's disease.

Authors:  Carla Piano; Marco Ciavarro; Francesco Bove; Daniela Di Giuda; Fabrizio Cocciolillo; Anna Rita Bentivoglio; Beatrice Cioni; Tommaso Tufo; Paolo Calabresi; Antonio Daniele
Journal:  NPJ Parkinsons Dis       Date:  2020-09-28

Review 2.  Motor cortex stimulation for pain and movement disorders.

Authors:  Jeffrey E Arle; Jay L Shils
Journal:  Neurotherapeutics       Date:  2008-01       Impact factor: 7.620

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.